Komori
Governance4570Immuno-Biological Laboratories Co.,Ltd.Pharmaceuticals

Notice Regarding the Transition to a Company with an Audit and Supervisory Committee

Subject to approval of the amendments to the Articles of Incorporation at the annual general meeting of shareholders scheduled for June 2026, the Company has decided to change from a company with a board of company auditors to a company with an audit and supervisory committee. Following the transition, audit and supervisory committee members will become members of the Board of Directors, and certain authority to make decisions on the execution of business will be delegable to directors.

Worth reading
70In focus
Scored from 1 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

Planned change from a company with a board of company auditors to a company with an audit and supervisory committee, subject to approval of the necessary amendments to the Articles of Incorporation at the 44th Annual General Meeting of Shareholders scheduled for June 2026
Committee1
Audit and supervisory committee (planned transition). The proportion of outside committee members is 非開示
Changes this time

The Company has decided to change from a company with a board of company auditors to a company with an audit and supervisory committee. Audit and supervisory committee members will become members of the Board of Directors, and the Board of Directors’ authority to make decisions on the execution of business is planned to be delegable to directors. The Company states that it will announce the amendments to the Articles of Incorporation and officer appointments once they have been decided.

Governance structure
ItemDetails
Corporate Governance StructurePlanned change from a company with a board of company auditors to a company with an audit and supervisory committee, subject to approval of the necessary amendments to the Articles of Incorporation at the 44th Annual General Meeting of Shareholders scheduled for June 2026
CommitteeAudit and supervisory committee (planned transition). The proportion of outside committee members is Not disclosed
Changes this timeThe Company has decided to change from a company with a board of company auditors to a company with an audit and supervisory committee. Audit and supervisory committee members will become members of the Board of Directors, and the Board of Directors’ authority to make decisions on the execution of business is planned to be delegable to directors. The Company states that it will announce the amendments to the Articles of Incorporation and officer appointments once they have been decided.
Items this document does not state (5)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The transition is intended to strengthen the Board of Directors’ oversight function by making audit and supervisory committee members members of the Board of Directors, thereby enhancing and strengthening corporate governance and achieving sustained growth in corporate value. It is also intended to accelerate decision-making and execution by making authority to make decisions on the execution of business delegable to directors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Transition to a Company with an Audit and Supervisory Committee | Immuno-Biological Laboratories Co.,Ltd. (4570) timely disclosure | Komori